SHEN Yi, WAN Qian, XIE Ning, XU Qing. Empirical research on the affordability of the antihypertensive drugs in the basic drug list from Qingpu District[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(6): 536-540. doi: 10.3969/j.issn.1006-0111.2018.06.013
| Citation:
|
SHEN Yi, WAN Qian, XIE Ning, XU Qing. Empirical research on the affordability of the antihypertensive drugs in the basic drug list from Qingpu District[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(6): 536-540. doi: 10.3969/j.issn.1006-0111.2018.06.013
|
Empirical research on the affordability of the antihypertensive drugs in the basic drug list from Qingpu District
- 1.
Department of Pharmacy, Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University, Shanghai 201700, China
- 2.
Department of Pharmacy, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, China
- Received Date: 2018-03-15
- Rev Recd Date:
2018-05-15
-
Abstract
Objective To evaluate the affordability of oral antihypertensive drugs in Qingpu District within the basic medication system and provide a substantial evidence for rationalizing the price of essential drugs to treat chronic diseases in communities. Methods WHO/HAI standardized method and dilution method were used to evaluate the affordability of the oral antihypertensive drugs in that area. Results The results of WHO/HAI standardized method showed that patients with health insurance had better affordability for brand name and generic medications. The uninsured patients had lower affordability for brand name medications. The results of dilution method showed that 5 medications available both in brand and generic forms had a smaller gap in the poverty population. The affordability of the brand name drug, Irbesartan, is higher than its generics. Conclusion Health insurance plays an important role in improving the affordability for essential drugs. Reasonable pricing should be given to the commonly used medications with clear evidence based data to improve the affordability of antihypertensive drugs.
-
References
|
[1]
|
WHO.Global Status Report on non-communicable diseases 2014[R].Switzerland:2014. |
|
[2]
|
WHO. Health Action International (2003) Measuring Prices, availability, affordability and price components,2nd edition[EB/OL].[2008-05-29].(2017-10-01). http://www.who.int/medicines/areas/access/medicines_prices08/en/. |
|
[3]
|
中国高血压防治指南修订委员会.中国高血压防治指南(2010年)[J]. 中华心血管病杂志,2011,(7):639-642. |
|
[4]
|
WHO Collaborating Centre for Drug Statistics Methodogy. ATC/DDD Index 2017[EB/OL].[2016-12-15].(2017-10-01). https://www.whocc.no/atc_ddd_index/ |
|
[5]
|
上海医保. 城乡居民基本医疗保险[EB/OL].(2017-10-01).http://www.shyb.gov.cn/xxcx/yb02.html. |
|
[6]
|
KE X. Distribution of health payments and catastrophic expenditures Methodology[R]. Geneva:WHO,2004. |
|
[7]
|
上海市统计局. 2016年上海统计年鉴[EB/OL].(2017-10-01). http://www.stats-sh.gov.cn/tjnj/nj16.htm?d1=2016tjnj/C1006.htm. |
|
[8]
|
上海市统计局. 2015年上海市国民经济和社会发展统计公报[EB/OL].[2016-02-29].(2017-10-01). http://www.stats-sh.gov.cn/html/sjfb/201602/287258.html. |
|
[9]
|
中华人民共和国国家统计局. 2015年分省年度数据[EB/OL].(2017-10-01). http://data.stats.gov.cn/easyquery.htm?cn=E0103. |
|
[10]
|
中华人民共和国民政部.2015年4季度各省社会服务统计数据[EB/OL].[2016-02-19].(2017-10-01). http://www.mca.gov.cn/article/sj/tjjb/sjsj/. |
|
[11]
|
国家卫生和计划生育委员会.中国卫生和计划生育统计年鉴(2016年)[M].北京:中国协和医科大学出版社,2016:237. |
|
[12]
|
叶露,胡善联, EWEN M,等. 上海市基本药物可负担性实证研究[J]. 中国卫生资源,2008,11(4):195-196. |
|
[13]
|
口服抗高血压药物临床试验的有效性评价中国专家共识编写组. 口服抗高血压药物临床试验的有效性评价中国专家共识[J]. 中华高血压杂志,2015,23(4):316-325. |
|
[14]
|
赵连友,孙宁玲,孙英贤,等.α/β受体阻滞剂在高血压治疗中应用的中国专家共识[J]. 中华高血压杂志,2016,24(6):522-527. |
|
[15]
|
李建平,卢新政,霍勇,等. H型高血压诊断与治疗专家共识[J]. 中华高血压杂志,2016,24(2):123-127. |
|
[16]
|
孙宁玲,秦献辉,李建平,等. 依那普利叶酸片固定复方与依那普利和叶酸自由联合在H型高血压人群中降低同型半胱氨酸的疗效比较[J]. 中国新药杂志,2009,18(17):1635-1640. |
-
-
Proportional views
-
DownLoad: